OPLE: Drug Discovery Platform Combining 2D Similarity with AI to Predict Off-Target Liabilities

<b>Background/Objectives</b>: An impediment to successful drug discovery is the potential for off-target liabilities to eliminate otherwise promising candidates. As the drug discovery process is time-consuming and expensive, the use of artificial intelligence (AI) methods such as machine learning (ML) has drastically increased. It is invaluable to generate models that can quickly differentiate between successful and unsuccessful small-molecule drug candidates. Previous efforts established that molecular similarity could be used with other metrics to inform predictions of potential activity against a protein target. Similar methods were pursued here to combine similarity and machine learning for a collection of models called OPLE. <b>Methods</b>: Models were trained with proprietary and publicly available data to predict the likelihood of a given compound to be active against targets present in existing experimental SafetyScreen panels 18 and 44. Two-dimensional (2D) Tanimoto similarity from extended-connectivity fingerprints (ECFPs) and trained ML models were combined to obtain predictions. <b>Results</b>: Using all training data, a relationship between similarity and activity was established by fitting a probability assignment curve. Calibrated ML label assignment likelihoods were joined with the predictions from ECFP Tanimoto similarity to known active compounds using the belief theory formula, which maintains that activity prediction increases when both pieces of evidence support it. When assessing the performance of OPLE models for SafetyScreen 18 and 44 targets with external data from ChEMBL, more than 80% of the models had recall values greater than 0.8. This indicated favorable predictive ability to identify active molecules while limiting false negative predictions. <b>Conclusions</b>: Predicting and experimentally verifying safety liabilities is insightful at every stage of small-molecule drug discovery. This early detection tool can help project teams save resources that could be better deployed on series with no predicted or measured off-target liabilities.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-01-28
DOI
https://doi.org/10.3390/ph19020228
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

OPLE: Drug Discovery Platform Combining 2D Similarity with AI to Predict Off-Target Liabilities

Fabien Tillier, Sarah E. Biehn, Christoph Mueller, Carleton R. Sage et al.
Pharmaceuticals
Computational Drug Discovery Methods
article

OPLE: Drug Discovery Platform Combining 2D Similarity with AI to Predict Off-Target Liabilities

Fabien Tillier, Sarah E. Biehn, Christoph Mueller, Carleton R. Sage, Juerg Lehmann
article en

Abstract

<b>Background/Objectives</b>: An impediment to successful drug discovery is the potential for off-target liabilities to eliminate otherwise promising candidates. As the drug discovery process is time-consuming and expensive, the use of artificial intelligence (AI) methods such as machine learning (ML) has drastically increased. It is invaluable to generate models that can quickly differentiate between successful and unsuccessful small-molecule drug candidates. Previous efforts established that molecular similarity could be used with other metrics to inform predictions of potential activity against a protein target. Similar methods were pursued here to combine similarity and machine learning for a collection of models called OPLE. <b>Methods</b>: Models were trained with proprietary and publicly available data to predict the likelihood of a given compound to be active against targets present in existing experimental SafetyScreen panels 18 and 44. Two-dimensional (2D) Tanimoto similarity from extended-connectivity fingerprints (ECFPs) and trained ML models were combined to obtain predictions. <b>Results</b>: Using all training data, a relationship between similarity and activity was established by fitting a probability assignment curve. Calibrated ML label assignment likelihoods were joined with the predictions from ECFP Tanimoto similarity to known active compounds using the belief theory formula, which maintains that activity prediction increases when both pieces of evidence support it. When assessing the performance of OPLE models for SafetyScreen 18 and 44 targets with external data from ChEMBL, more than 80% of the models had recall values greater than 0.8. This indicated favorable predictive ability to identify active molecules while limiting false negative predictions. <b>Conclusions</b>: Predicting and experimentally verifying safety liabilities is insightful at every stage of small-molecule drug discovery. This early detection tool can help project teams save resources that could be better deployed on series with no predicted or measured off-target liabilities.

PharmaceuticalsVol. 19(2)
Beilstein-Institut (DE), Eurofins (Norway) (NO)
Openalex Percentile: Top 72%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.